Abstract. Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1) have been tested in clinical trials, and anti-PD-1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD-1, PD-L1 and programmed cell death protein 1 ligand 2 (PD-L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) were positive for PD-L1 expression and 45.8% (22/48) were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P=0.049).
Introduction
Lung cancer is the most common cause of cancer-associated mortalities worldwide (1) . The American Cancer Society estimated that there would be ~221,200 novel cases and ~158,040 mortalities caused by lung cancer in the USA in 2015 (1, 2) . Lung cancer is the second most common malignancy and the most common cause of cancer-associated mortality in American men and women (1) . In China, novel cases and lung cancer-associated mortalities were estimated to be 536,407 and 475,768, respectively, in 2005 (2) . Globally, it has been estimated that there were 1,824,700 novel cases and 1589,900 lung cancer-associated mortalities in 2012 (3) .
Currently, surgical resection remains the standard of care for the majority of patients with non-metastatic non-small cell lung cancer (NSCLC). Cancer immunotherapy has recently received attention (4) , since the United States Food and Drug Administration (FDA) approved Provenge ® (sipuleucel-T) for the treatment of metastatic castration-resistant prostate cancer and Yervoy ® (ipilimumab) for the treatment of metastatic melanoma (5, 6) . Inhibitors of the programmed cell death protein 1 (PD-1), an immunosuppressive checkpoint protein, and the programmed cell death protein 1 ligand 1 (PD-L1) and ligand 2 (PD-L2), have demonstrated positive outcomes in the treatment of cancers, including lung cancer, in clinical trials (7) .
A phase I clinical trial reported objective responses in approximately 1/4 to 1/5 of patients with NSCLC, melanoma and renal-cell cancer, who were treated with anti-PD-1 antibodies (8) . Another phase I clinical trial reported objective response rates of 6-17% and a stabilization of disease at rates of 12-41% at 24 weeks in patients with advanced cancers, including NSCLC, melanoma and renal-cell cancer, who were treated with anti-PD-L1 antibodies (9) . Three patients sustained long-term partial or complete response in 16 months to 3 years following treatment (10 produced a response rate of ~38% in melanoma patients, with or without prior ipilimumab treatment (11) . A combination of anti-PD-1 antibody (nivolumab) and ipilimumab produced a 53% objective response in the patients with advanced melanoma (12) . A phase III trial showed that anti-PD-1 antibody (pembrolizumab, also called lambrolizumab or MK-3475) produced a significantly better response rate (~33%) compared with ipilimumab (11.9%; P<0.001) in the treatment of advanced melanoma (13) . A recent phase I trial showed that pembrolizumab produced an objective response rate of 19.4% in 495 patients with NSCLC. The median duration of progression-free survival was 3.7 months and the median duration of overall survival was 12.0 months (14) . Therefore, on September 4, 2014, the FDA granted accelerated approval to the anti-PD-1 antibody pembrolizumab (Keytruda ® ; Merck & Co, Inc., Whitehouse Station, NJ, USA) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if B-Rapidly Accelerated Fibrosarcoma (BRAF) V600 mutation positive, a BRAF inhibitor such as vemurafenib, sorafenib or dabrafenib. The FDA also approved nivolumab (Opdivo ® ; Bristol-Myers Squibb Company, Princeton, NJ, USA) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor for the treatment of patients with metastatic squamous NSCLC with progression during or following platinum-based chemotherapy, on December 22, 2014 and March 4, 2015, respectively. FDA assigned a priority review designation to pembrolizumab (Keytruda ® ) as a treatment for patients with advanced NSCLC and a final approval decision will be made in the future. Anti-PD-L1 antibody (MPDL3280A; Genentech; Roche, South San Francisco, CA, USA) showed responsive rates of 13-26% in solid tumors, including NSCLC (15) . On February 2, 2015, the FDA gave MPDL3280A a breakthrough therapy designation for the treatment of PD-L1-positive NSCLC that has progressed during or following platinum-based chemotherapy, as well as a targeted therapy for patients with epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive tumors. MPDL3280A is currently undergoing phase II and III trials to obtain FDA approval (16) .
PD-1 was originally identified by Ishida et al (17) in search of genes responsible for programmed cell death. The study cloned a gene encoding a protein with 288 amino acids, which was activated during programmed cell death; therefore, the protein was named PD-1 (17) . Disruption of the PD-1 gene led to development of lupus-like arthritis and glomerulonephritis, indicating that PD-1 is a negative regulator of immune responses (18, 19) . Honjo and Freeman et al (20) collaboratively identified PD-L1, which is identical to B7-H1 reported by Dong et al (21) . Latchman et al (22) further identified a second PD-1 ligand PD-L2, which is identical to B7-DC (23) . The binding of PD-1 by PD-L1 and PD-L2 is now known to inhibit T cell receptor-mediated lymphocyte proliferation and cytokine secretion, thus suppressing immune responses (24) . In the tumor microenvironment, the PD-1-PD-L1/L2 pathway is upregulated, resulting in the immune evasion of tumor cells (22, 25) . Therefore, the antibodies against PD-1, PD-L1 and likely PD-L2 may block the immune evasion response and induce tumor regression.
PD-1, a negative costimulatory receptor, is primarily expressed on the cellular surface of activated T cells (26, 27) . PD-L1 is expressed by tumor cells and tumor-infiltrating immune cells, including macrophages, dendritic cells and T cells (15) . PD-L1 and PD-L2 mRNAs are expressed in the human heart, placenta, spleen, lymph nodes and thymus tissues. In addition, PD-L2 messenger RNA (mRNA), but not PD-L1 mRNA, is expressed in the human lung, liver, smooth muscle and pancreas tissues (22) . In a cohort of 824 NSCLC patients, ≥50% of tumor cells stained positive for PD-L1 in 23.2% of patients, 1-49% of tumor cells stained positive for PD-L1 in 37.6% of patients and <1% of tumor cells stained positive for PD-L1 in 39.2% of patients (14) . The objective response rate (ORR) to pembrolizumab treatment is positively associated with the percentage of tumor cells with membranous PD-L1 staining, for example: Patients that were <1% PD-L1+ exhibited an 8.1% ORR; patients that were 1-24% PD-L1+ exhibited a 12.9% ORR; patients that were 25-49% PD-L1+ exhibited a 19.4% ORR; patients that were 50-74% PD-L1+ exhibited a 29.6% ORR; and patients that were 75-100% PD-L1+ exhibited a 45.4% ORR (14) . In contrast, in a cohort of 272 squamous NSCLC, the ORRs to nivolumab treatment were similar between PD-L1+ and PD-L1-tumors, namely: Patients that were <1% PD-L1+ exhibited a 17% ORR; patients that were ≥1% PD-L1+ exhibited a 17% ORR; patients that were <5% PD-L1+ exhibited a 15% ORR; patients that were ≥5% PD-L1+ exhibited a 21% ORR; patients that were <10% PD-L1+ exhibited a 16% ORR; and patients that were ≥10% PD-L1+ exhibited a 19% ORR). This discrepancy may be due to the differences in sample size or antibodies. However, additional studies are required to assess expression of PD-1, PD-L1 and PD-L2 in NSCLC. Although Keytruda ® and Opdivo ® are not yet approved for use in China, their eventual approval is possible.
Therefore, the objective of this study was to assess expression of PD-1, PD-L1, and PD-L2 in 48 cases of NSCLC in China. We found that PD-L1, but not PD-1 or PD-L2 expression was associated with stage III NSCLC.
Materials and methods
Human lung cancer tissue samples. The present study was approved by the Institutional Review Board of The Fourth Hospital of Hebei Medical University (Shijiazhuang, China). The procedures to obtain human lung cancer tissue and follow-up information were in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as formulated in the World Medical Association Declaration of Helsinki (revised 2008). All human lung cancer tissue samples were obtained from the archives of formalin-fixed, paraffin-embedded tissue blocks in the Department of Thoracic Surgery at The Fourth Hospital of Hebei Medical University (Shijiazhuang, China). The specimens were collected from surgeries performed between April 2010 and March 2013. Written informed consent was obtained from all patients prior to surgery. The patients were followed up until March 2015, through outpatient visits or correspondences to family members. In total, 48 patients were included in this retrospective study. Tumor stage was evaluated according to the Union for International Cancer Control (UICC) 7th TNM classification system and histological evaluation was based on the World Health Organization criteria (28) . The clinicopathological characteristics of the patients are summarized in Table I .
Immunohistochemistry. Tissue sections (4-µm thick) were baked at 60˚C for 60 min, deparaffinized in xylene and rehydrated through graded ethanol solutions to water. Antigens were retrieved by heating the tissue sections in 0.01 M ethylenediaminetetraacetic acid buffer at 95˚C for 5 min and then cooling down to room temperature in 20 min. Endogenous peroxidase activity was blocked by 0.3% H 2 O 2 for 5 min. Non-specific binding was blocked with 1.5% normal goat or horse serum (VECTASTAIN Elite ABC kit; Vector Laboratories, Burlingame, CA, USA). The sections were incubated with primary antibodies in a humid chamber at 4˚C overnight: Rabbit anti-human PD-L1 polyclonal antibodies (catalog no., ab58810; dilution, 1:40; Abcam, Cambridge, MA, USA), rabbit anti-human PD-L2 polyclonal antibodies (catalog no., SAB3500395-100UG; dilution, 1:800; Sigma-Aldrich, St. Louis, MO, USA) and mouse anti-human cluster of differentiation (CD)279 (PD-1) purified monoclonal antibodies (catalog no., 14-9989-82; dilution, 1:25; eBioscience, Inc., San Diego, CA, USA) were used as the primary antibodies. Subsequent to being washed 3 times in phosphate-buffered saline, the sections were incubated with secondary antibodies from the VECTA-STAIN Elite ABC kit for 120 min. The color was developed using 3,3'-diaminobenzidine (DAB) substrate kit (Vector Laboratories) following the manufacturer's protocol. The sections were then counterstained with hematoxylin. Tissue sections that had previously stained positively were used as a positive control and tissue sections stained with non-immune serum rather than primary antibodies served as a negative control. Positive staining showed brown particles at the cytoplasmic membrane or in the cytoplasm. Under a microscope, 5 representative high-power (magnification, x400) fields, containing tumor islet cells and stroma, per tissue section were randomly selected and evaluated by two investigators (Dr Zhiquan Chen from Hebei Medical University, Shijiazhuang, China, and Dr Jiandong Mei from Sichuan University, Chengdu, China), who were blinded to the clinicopathological characteristics. An average of the scores obtained by the two examiners was used to represent each case. A two-score system based on a proportion score and an intensity score, previously described by Allred et al (29) , was used. The proportion scores were assigned based on the percentage of positive staining: 0, none; 1, <1%; 2, 1-10%; 3, 10-33.3%; 4, 33.3-66.7%; and 5, >66.7%. The intensity scores were assigned based on the estimated average staining intensity of positive staining: 0, none; 1, weak; 2, intermediate; and 3, strong. The overall Allred scores (29) were the sum of the proportion score and intensity score of each case (range, 0-8).
Statistical analysis. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 16.0 for Windows (SPSS, Chicago, IL, USA). The results were presented as the mean ± standard deviation (SD) or median and range for numerical variables. The comparison of clinicopathological characteristics between various groups was performed using the χ 2 test. Spearman's rank correlation coefficient was calculated to reveal the correlation between PD-1, PD-L1 and PD-L2 scores. The survival time of various groups was described using Kaplan-Meier curves, and the statistical significance was analyzed using the log-rank test. P<0.05 was considered to indicate a statistically significant difference. 
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Results
PD-1, PD-L1 and PD-L2 are expressed in NSCLC.
Immunohistochemical staining revealed that PD-1 was expressed in the immune cells that were located mostly in the stroma of lung adenocarcinomas and squamous cell carcinomas (Fig. 1) . PD-L1 and PD-L2 were expressed in the cancer cells of lung adenocarcinomas and squamous cell carcinomas (Fig. 1) .
PD-L1, but not PD-1 or PD-L2, is associated with stage III lung cancer.
To assess whether the expression of PD-1, PD-L1 and PD-L2 is correlated with any clinicopathological characteristics of the patients, any staining (Allred score ranges 1-8) was defined as positive (+) and no staining (Allred score= 0) was defined as negative (-). Analysis revealed that neither PD-1 nor PD-L2 expression was associated with the patients' gender, tumor histological types, tumor differentiation, tumor stage or status of lymph node metastasis (Tables II and III) . PD-L1 expression was not associated with the patients' gender, tumor histological types, tumor differentiation or status of lymph node metastasis (Table IV) . However, PD-L1 expression was associated with the tumor stage (P= 0.049). The positive staining rate was 55.9% (19/34) in the stage 1/II tumors, whereas it was 85.7% (12/14) in the stage III tumors (Table IV) .
PD-1, PD-L1 and PD-L2 expression is independent of each other in lung cancer.
Correlation analysis found that the expressions of PD-1, PD-L1 and PD-L2 were independent of each other. No correlation was identified between PD-1 and PD-L1 expression, PD-1 and PD-L2 expression or PD-L1 and PD-L2 expression ( Fig. 2 ; Table V) .
PD-1, PD-L1 and PD-L2 expression is not associated with the survival time in lung cancer patients.
Kaplan-Meier analysis showed that PD-1, PD-L1 and PD-L2 expression was not associated with the survival time of patients with lung cancer (Fig. 3) .
Increased levels of PD-1 expression appeared to be inversely Table III . Association between PD-L2 expression and clincopathological characteristics of patients. Table V . Correlation between PD-1 and PD-L1 or PD-L2 expression. Table IV . Association between PD-L1 expression and clincopathological characteristics of patients. associated with the survival time; however, this result was not statistically significant (Fig. 3) . In addition, the survival time of patients with tumors that were positively stained for PD-1, PD-L1 and PD-L2 expression was not significantly different from the survival time of patients with negatively stained tumors (Fig. 4) .
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Discussion
In the present study of a cohort of 48 patients with NSCLC, 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) of patients were positive for PD-L1 expression and 45.8% (22/48) of patients were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis. However, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P= 0.049). The lack of statistically significant associations with the majority of the clinicopathological characteristics may be due to the small sample size used in the present study. In a cohort of 331 patients with squamous NSCLC in a previous study, neither PD-L1 nor PD-L2 expression was associated with gender, age, smoking history, tumor size, tumor stage or lymph node metastasis (30) . However, PD-L1 expression was marginally associated with tumor stage (P=0.059) (30) . The present study also found that the expressions of PD-1, PD-L1 and PD-L2 were independent of each other, which is consistent with the previous study (30) . This independence may suggest that any component of the PD-1-PD-L1/L2 pathway may be upregulated to suppress immune responses in the tumor microenvironment. In addition, the present study indicated that the expression of PD-1, PD-L1 and PD-L2 was not associated with the survival of the patient.
In a meta-analysis of 9 studies that included 1,550 NSCLC patients, PD-L1 expression was associated with differentiation status, but not with gender, smoking status, histology, tumor stage or lymph node status (31) . These findings suggest that PD-L1 may have limited use for predicting prognosis. The present study provides essential information regarding the expression of PD-1, PD-L1 and PD-L2 in patients with NSCLC, which may be useful for guiding future treatment with Keytruda ® and Opdivo ® . Given the unsatisfactory clinical outcomes with current therapies, the adoption of immunotherapy may help to improve the survival rate of our patients.
